Urol. praxi. 2023;24(3):140-145 | DOI: 10.36290/uro.2023.061

Immunotherapy in kidney tumours

MUDr. Andrea Ondrušková, doc. MUDr. Hana Študentová, Ph.D.
Onkologická klinika LF UP a FN Olomouc

Malignant kidney tumours are a frequent malignancy, with the Czech Republic having the highest rates of incidence in Europe. Treatment options for this disease have advanced greatly in recent years. Both advances in modern surgical methods and treatment with tyrosine kinase inhibitors (TKIs) have significantly contributed to the decreasing morbidity rates and improved survival rates. Major progress has been achieved with the inclusion of immunotherapy in the treatment regimens for this disease. This article deals with immunotherapy alone, combined immunotherapy, as well as the combination of immunotherapy with TKIs.

Keywords: immunotherapy, combined immunotherapy, checkpoint inhibitors, kidney tumour, RCC, mRCC, kidney tumour treatment.

Accepted: September 25, 2023; Published: October 2, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ondrušková A, Študentová H. Immunotherapy in kidney tumours. Urol. praxi. 2023;24(3):140-145. doi: 10.36290/uro.2023.061.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bukavina L, Bensalah K, Bray F, et al. Epidemiology of Renal Cell Carcinoma: 2022 Update. Eur Urol. 2022;82(5):529-542. doi: 10.1016/j.eururo.2022.08.019. Epub 2022 Sep 10. PMID: 36100483. Go to original source... Go to PubMed...
    2. Krejčí D, Pehalová L, Talábová A, et al. Novotvary 2018 ČR: Současné epidemiologické trendy novotvarů v České republice [Internet]. 2018. [cit. 2023-02-26]. ISSN 1210-857X. Available from: https://www.uzis.cz/res/f/008352/novotvary2018.pdf.
    3. Moch H, Amin MB, Bernea DM, et al. The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs - Part A: Renal, Penile, and Testicular Tumours. European Urology [Internet]. 2022;82(5):458-468. [cit. 2023-03-16]. ISSN 03022838. Available from: doi:10.1016/j.eururo.2022.06.016. Go to original source... Go to PubMed...
    4. Magee DE, Helstrom E, Kutikov A. The role of cytoreductive nephrectomy in the immuno-oncological therapy era. Curr Opin Urol. 2023;33(2):136-141. doi: 10.1097/MOU.0000000000001077. Epub 2023 Jan 9. PMID: 36710594. Go to original source... Go to PubMed...
    5. Studentova H, Rusarova N, Ondruskova A. The Role of Cytoreductive Nephrectomy in Renal Cell Carcinoma with Sarcomatoid Histology: a Case Series and Review of the Literature. Curr Oncol. 2022;29(8):5475-5488. doi: 10.3390/curroncol29080433. PMID: 36005171; PMCID: PMC9406807. Go to original source... Go to PubMed...
    6. Escudier B, Porta C, Schmidinger M, et al. ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Renal cell carcinoma: ESMO Clinical Practice Gui­delines for diagnosis, treatment and follow-up†. Ann Oncol. 2019;30(5):706-720. doi: 10.1093/annonc/mdz056. PMID: 30788497. Go to original source... Go to PubMed...
    7. Bosma NA, Warkentin MT, Gan CL, et al. Efficacy and Safety of First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis. Eur Urol Open Sci. 2022;37:14-26. doi: 10.1016/j.euros.2021.12.007. PMID: 35128482; PMCID: PMC8792068. Go to original source... Go to PubMed...
    8. Tang Q, Chen Y, Li X, et al. The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers. Front Immunol. 2022;13:964442. doi: 10.3389/fimmu.2022.964442. PMID: 36177034; PMCID: PMC9513184. Go to original source... Go to PubMed...
    9. Escudier B, Porta C, Schmidinger, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology [Internet]. 2019;30(5):706-720. [cit. 2023-02-26]. ISSN 09237534. Dostupné z: doi:10.1093/annonc/mdz056. Go to original source... Go to PubMed...
    10. Choueiri TK, Tomczak P, Park SH, et al. Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. New England Journal of Medicine [Internet]. 2021;385(8):683-694. [cit. 2023-03-02]. ISSN 0028-4793. Available from z: doi:10.1056/NEJMoa2106391. Go to original source... Go to PubMed...
    11. Pal SK, Uzzo S, Karam JA, et al. Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial. The Lancet [online]. 2022;400(10358):1103-1116. [cit. 2023-03-16]. ISSN 01406736. Available from: doi:10.1016/S0140-6736(22)01658-0. Go to original source... Go to PubMed...
    12. Motzer RJ, Haas NB, Donskov F, et al. PROTECT investigators. Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma. J Clin Oncol. 2017;35(35):3916-3923. doi: 10.1200/JCO.2017.73.5324. Epub 2017 Sep 13. PMID: 28902533; PMCID: PMC6018511. Go to original source... Go to PubMed...
    13. Motzer RJ, Ravaud A, Patard JJ, et al. Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results. Eur Urol. 2018;73(1):62-68. doi: 10.1016/j.eururo.2017.09.008. Epub 2017 Sep 28. PMID: 28967554; PMCID: PMC6684251. Go to original source... Go to PubMed...
    14. Martini DJ, Liu Y, Shabto JM, et al. Novel Risk Scoring System for Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. Oncologist. 2020;25(3):e484-e491. doi: 10.1634/theoncologist.2019-0578. Epub 2019 Dec 5. PMID: 32162798; PMCID: PMC7066702. Go to original source... Go to PubMed...
    15. Kiss I, Adámková Krákorová D, Andrašina T, et al. Modrá kniha České onkologické společnosti, 28. aktualizace, Brno, Masarykův onkologický ústav. 2022. ISBN: 978-80-86793-53-5.
    16. Choueiri TK, Tomczak P, Park SH, et al. Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. N Engl J Med. 2021;385:683-694. Go to original source... Go to PubMed...
    17. Powles T, Tomczak P, Park SH, et al. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23(9):1133-1144. Go to original source... Go to PubMed...
    18. George D, Jonasch E. Systemic therapy of advanced clear cell renal carcinoma [Internet]. [cit. 2023-02-26]. Available from: https://www.uptodate.com/contents/systemic-therapy-of-advanced-clear-cell-renal-carcinoma?search=ipilimumab%20nivolumab&source=search_result&selectedTitle=5~91&usage_type=default&display_rank=5.
    19. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma, New England Journal of Medicine [Internet]. 373. 2015 [cit. 2023-02-26]. ISSN 0028-4793. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1510665.
    20. Rini B, Plicmack ER, Stus V, et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. New England Journal of Medicine [Internet]. 2019;380(12). [cit. 2020-07-28]. DOI: 10.1056/NEJMoa1816714. ISSN 0028-4793. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1816714. Go to original source... Go to PubMed...
    21. Poprach A, Lakomý R. New treatment options for metastatic renal cell carcinoma [Internet]. 20-24 [cit. 2023-02-26]. ISSN 18024475. Dostupné z: doi:10.36290/xon.2022.004. Go to original source...
    22. Choueiri TK, Powles T, Burotto M, et al. Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. New England Journal of Medicine [Internet]. 2021;384(9):829-841. [cit. 2023-03-16]. ISSN 0028-4793. Available from: doi:10.1056/NEJMoa2026982. Go to original source... Go to PubMed...
    23. Motzer R, Alekseev B, Rha SY, et al. CLEAR Trial Investigators. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. N Engl J Med. 2021;384(14):1289-1300. Go to original source... Go to PubMed...
    24. Choueiri TK, Eto M, Motzer R, et al. Lenvatinib plus Pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study. Lancet Oncol. 2023;23:228-238. Go to original source... Go to PubMed...
    25. Motzer RJ, Tannir NM, McDermott DF, et al. CheckMate 214 Investigators. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018;378(14):1277-1290. doi: 10.1056/NEJMoa1712126. Epub 2018 Mar 21. PMID: 29562145; PMCID: PMC5972549. Go to original source... Go to PubMed...
    26. Motzer RJ, Penkov K, Hannen J, et al. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. New England Journal of Medicine [Internet]. 2019;380(12):1103-1115 [cit. 2023-03-16]. ISSN 0028-4793. Available from: doi:10.1056/NEJMoa1816047. Go to original source... Go to PubMed...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.